AXSM
Axsome Therapeutics Inc
NASDAQ: AXSM · HEALTHCARE · BIOTECHNOLOGY
$207.75
+12.94% today
Updated 2026-04-30
Market cap
$9.46B
P/E ratio
—
P/S ratio
14.82x
EPS (TTM)
$-3.68
Dividend yield
—
52W range
$96 – $193
Volume
0.7M
Axsome Therapeutics Inc (AXSM) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.63M | $-4.60M | $-7.44M | $-21.28M | $-26.47M | $-30.05M | $-46.38M | $-78.46M | $-108.23M | $-116.51M | $-145.08M | $-128.41M | $-93.41M |
| Capital expenditures | $0.00 | $20195.00 | $20195.00 | $104561.00 | $9898.00 | $32696.00 | $16121.00 | $45891.00 | $308000.00 | $702000.00 | $582000.00 | $270000.00 | $480000.00 |
| Depreciation | — | $3542.00 | $3542.00 | $20484.00 | $42557.00 | $48935.00 | $37330.00 | $77718.00 | $76000.00 | $4.40M | $6.83M | $7.96M | — |
| Stock-based comp | $55281.00 | $376806.00 | $803279.00 | $2.03M | $2.07M | $1.75M | $6.12M | $14.76M | $20.80M | $37.73M | $62.62M | $85.22M | $93.75M |
| Free cash flow | $-1.63M | $-4.62M | $-7.46M | $-21.39M | $-26.48M | $-30.09M | $-46.39M | $-78.50M | $-108.53M | $-117.21M | $-145.66M | $-128.68M | $-93.89M |
| Investing cash flow | — | $-20195.00 | $-20195.00 | $-104561.00 | $-9898.00 | $-32696.00 | $-16121.00 | $-45891.00 | $-308000.00 | $-53.70M | $-582000.00 | $-270000.00 | — |
| Financing cash flow | $3.72M | $5.13M | $52.88M | $9.97M | $23.88M | $10.03M | $252.39M | $42.41M | $11.13M | $284.58M | $331.01M | $57.84M | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | — | — | — | — | $43.98M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-11.42M | $-2.60M | $-20.05M | $206.00M | $-36.09M | $-97.40M | — | — | — | — |